GLP-1 weight loss — no needles required.

At the 25 mg maintenance dose studied in the OASIS 4 trial, the Wegovy pill produced meaningful weight loss (around 13.6% mean reduction at 64 weeks under the treatment-policy estimand, and approximately 16.6% with full adherence). That's closer to injectable Wegovy's results than Rybelsus ever got close to.

That said, injectable Wegovy at 2.4 mg weekly still has a slight edge in some head-to-head comparisons, and Zepbound (tirzepatide injection) produces greater weight loss than either oral semaglutide or injectable semaglutide.

Dose. Rybelsus tops out at 14 mg daily and is FDA-approved for type 2 diabetes (weight loss is a secondary effect in those trials). The Wegovy pill is 25 mg daily and was studied specifically for obesity.

The "same active ingredient" framing is accurate — but dose matters. In PIONEER PLUS, oral semaglutide at 25 mg and 50 mg produced substantially more weight loss than 14 mg. The Wegovy pill is essentially a higher-dose, obesity-indicated version of what's in Rybelsus.

Foundayo (orforglipron) is Eli Lilly's oral GLP-1, FDA-approved on April 1, 2026. Unlike the Wegovy pill (which is a peptide requiring strict empty-stomach dosing), Foundayo is a small-molecule drug that can be taken at any time of day with or without food and no water restrictions. That's a significant convenience advantage.

In the ATTAIN-1 trial, patients on the highest dose of Foundayo lost an average of 12.4% of body weight over 72 weeks. That's meaningful but somewhat less than Wegovy pill's 13.6–16.6% in OASIS 4. Self-pay pricing for both starts at $149/mo for starter doses via manufacturer programs.

No. Tirzepatide is a 4,813-dalton peptide — roughly 10 times larger than what's considered feasible for oral absorption. It's too large to survive the stomach and cross intestinal cells in any meaningful quantity.

Telehealth companies selling "oral tirzepatide" as drops, lozenges, or gum are selling compounded products without published human absorption or efficacy data. In late 2025, a class-action lawsuit alleging misleading marketing of compounded oral tirzepatide was filed against OpenLoop Health and Triad Rx.

Eli Lilly's oral GLP-1 strategy deliberately went a different direction: Foundayo (orforglipron) is a small-molecule drug specifically designed for oral absorption — not an oral tirzepatide.

Compounded medications are not FDA-approved. That means the FDA has not reviewed them for safety, efficacy, or manufacturing quality the way it reviews brand drugs like Wegovy pill or Rybelsus.

A compounded product prepared by a licensed, accredited pharmacy operating within federal Section 503A rules is not inherently dangerous — but you're relying on the pharmacy's quality controls rather than FDA oversight. We strongly recommend providers that publish their pharmacy partners, hold LegitScript certification, and have no FDA warning letters on record.

Since February 2026, the FDA has issued warning letters to several high-profile telehealth compounding platforms for misleading marketing. Check our provider reviews for the latest status on specific companies.

For FDA-approved drugs, the starter dose of the Wegovy pill (1.5 mg) and Foundayo (0.8 mg) are both priced at $149/month self-pay through manufacturer direct programs. With commercial insurance and savings programs, both can come down to around $25/month for eligible patients.

For compounded oral GLP-1s, the cheapest published rates are around $147–$169/mo depending on provider and format (Wellorithm and MadeMed sublingual sema, respectively). Just remember: compounded is not FDA-approved, and at these starter-dose price points the FDA-approved pill is essentially at parity.

That's a conversation for you and your prescribing clinician, but a few considerations: if you're currently on Zepbound (tirzepatide) and losing weight well, switching to an oral semaglutide product would likely mean giving up some efficacy. If you're on Wegovy injection and tolerating it, switching to the Wegovy pill is a comparable-efficacy option at potentially lower cost.

Key practical point: the Wegovy pill needs to be taken on an empty stomach with no more than 4 oz of plain water, waiting 30 minutes before eating or drinking anything else. Foundayo has no food/water restrictions — a big adherence advantage for some people.

Sometimes, for approved indications. Rybelsus (diabetes) is more likely to be covered than Wegovy pill or Foundayo (obesity). Commercial plans often require prior authorization and BMI documentation. Medicare generally doesn't cover GLP-1s for weight loss alone, though the BALANCE pilot program beginning July 2026 may change that for some Part D enrollees.

Even without coverage, manufacturer savings programs can substantially reduce costs: Novo Nordisk offers Wegovy pill at $149/month self-pay for starter doses, and Eli Lilly offers Foundayo at the same starter price through LillyDirect. Compounded products are cash-pay only and don't accept insurance.

The side effect profile of oral semaglutide is similar to injectable semaglutide: nausea (most common), diarrhea, constipation, vomiting, and abdominal pain. Most GI side effects are mild to moderate and improve over the first few weeks as you titrate up in dose.

The Wegovy pill also carries the class-wide black box warning for thyroid C-cell tumors in rodent studies. Foundayo has a similar GI profile plus the same thyroid warning. Less common but serious effects can include pancreatitis, gallbladder problems, and gastroparesis.

Work with a clinician who can help manage side effects and titrate appropriately.